Nov 30, 2022 / 12:50AM GMT
Takeshi Iwatsubo -
Good afternoon, everyone. I welcome to the symposium on Clarity AD, a Phase III placebo-controlled, double-blind, parallel-group, 18 months study evaluating lecanemab in early Alzheimer's disease. I'm Takeshi Iwatsubo from the University of Tokyo. I'm honored and very thrilled to chair this historic session in Alzheimer's research on therapeutics.
Many of you may well remember that on September 27 of this year, the top line results of Clarity AD as a first large completed a positive Phase III trial of disease modifying therapy of AD was announced, which represent a monumental event for patients and their families living with Alzheimer's disease and all scientists in this field, Eisai based in Koishikawa, Tokyo, and then headed by Mr. Haruo Naito, who is also here today, has been at the forefront of Alzheimer's Research over the past 4 decades from developing a symptomatic breakthrough treatment in the 1980s and '90s to the current industry-leading antibody development. The approach rose naturally from the human health care mission.
At this present session, 5 distinguished
Eisai Co Ltd Clarity AD Study Briefing Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers